Semaglutide's influence on warfarin pharmacokinetics/pharmacodynamics and metformin pharmacokinetics investigated in healthy subjects

Patients with Type 2 Diabetes Mellitus (T2DM) and obesity often require long-term medication, including semaglutide, a highly effective GLP-1 receptor agonist. These patients frequently have comorbidities like cardiovascular disease, necessitating co-administration with other drugs such as warfarin (an anticoagulant) or metformin (a first-line T2DM therapy). Understanding potential drug-drug interactions (DDIs) is critical to ensure patient safety and maintain therapeutic efficacy, especially for drugs with narrow therapeutic windows like warfarin. This study addresses the crucial need to characterize how semaglutide might alter the absorption, distribution, metabolism, and excretion (PK) and effects (PD) of these commonly co-prescribed medications.

This Phase 1 clinical trial, conducted across sites in Europe and Asia, aimed to investigate the potential for semaglutide to influence the pharmacokinetics (PK) and pharmacodynamics (PD) of warfarin, and the PK of metformin, in healthy adult subjects. The study design focused on assessing drug exposure and effects when semaglutide was co-administered with these established medications. Specific details regarding the number of participants (n), the exact dose and route of semaglutide, warfarin, or metformin, the duration of treatment, or the primary endpoints (e.g., specific INR targets for warfarin PD, or AUC/Cmax for PK) are not provided in the abstract. The trial's primary objective was to characterize any changes in the systemic exposure or biological activity of warfarin and metformin when semaglutide was present.

The provided abstract describes the aim of the trial but does not report any specific findings or results. Therefore, no data, statistical values, percentages, or fold-changes from the study are available to be presented in this section. The abstract outlines the intention to investigate the influence of semaglutide on the pharmacokinetics and pharmacodynamics of warfarin, and the pharmacokinetics of metformin, in healthy subjects, but does not disclose the outcomes of this investigation.